Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01035996 · ClinicalTrials.gov registry record
Dopamine Function and Reward Processing In Schizophrenia
A clinical trial of Schizophrenia, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- 159
- Enrollment target
- 2
- Study locations
NCT01035996: Completed study of Schizophrenia, sponsored by National Institute on Drug Abuse (NIDA).
NCT01035996 is a study of Schizophrenia that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 159 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (27% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01035996, a study of Schizophrenia, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- 159 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: \- Schizophrenia is associated with cognitive impairment in different parts of the brain, including those associated with learning and memory. The brain activity associated with these impairments, however, is poorly understood. Researchers are interested in studying how the brain chemical dopamine, which is involved in responding to incentives and rewards like money or food, works differently in the brains of people who have schizophrenia. Objectives: \- To study reward processing in individuals with schizophrenia who are taking different types of medication, compared with healthy volunteers. Eligibility: \- Individuals between 18 and 55 years of age who (a) have been diagnosed with schizophrenia/schizoaffective disorder and are taking the antipsychotic medication clozapine, (b), have been diagnosed with schizophrenia/schizoaffective disorder and are taking a different second-generation antipsychotic, or (c) are healthy volunteers. Design: * This study will involve one screening visit and one or more visits for testing and functional magnetic resonance imaging (fMRI) scans. During the screening visit, participants will complete questionnaires and provide information about their physical and psychological health. * Participants will receive training in the tasks to be performed at the scanning sessions during the screening visit. * During the fMRI scans, participants will complete one or two of four possible reward-based tasks: * A task that enables participants to win money based on their response to a target item. * A task that provides small amounts of juice over specific time intervals, followed by a procedure to be completed outside the scanner. * A task that involves choosing figures or shapes and winning money based on responses. * A game of chance involving predictions based on shapes shown on a screen. * Participants will also provide blood samples for research and testing.
Conditions Studied
Study Locations (2)
Maryland
- University of Maryland, Baltimore - Baltimore
- National Institute on Drug Abuse, Biomedical Research Center (BRC) - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2005-03-08 |
| Est. Completion | 2017-02-13 |
What the finished NCT01035996 record still lists
NCT01035996 is an observational study that tracks outcomes without assigning an intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (27% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 0 interventions.
NCT01035996 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01035996 about?
NCT01035996 is a clinical study titled "Dopamine Function and Reward Processing In Schizophrenia". Background: \- Schizophrenia is associated with cognitive impairment in different parts of the brain, including those associated with learning and memory. The brain activity associated with these impairments, however, is poorly understood. Researchers are interested in studying how the brain chemic...
What is the current status of trial NCT01035996?
This trial is currently completed. The enrollment target is 159 participants. The study started on 2005-03-08. Estimated completion is 2017-02-13.
What conditions does trial NCT01035996 study?
This clinical trial studies the following conditions: Schizophrenia.
Who is sponsoring clinical trial NCT01035996?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01035996 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01035996's enrollment target sits among peer trials
159 105th of 315 higher than 211 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI